Shandong Boan Biotech swings to FY26 H1 net loss of RMB 83.01 million; revenue drops 40.8% to RMB 233 million

• Shandong Boan Biotech swung to a net loss of RMB 83 million for the six months ended June 30, 2026, from profit a year earlier.
• Revenue fell 40.8% to RMB 233 million, due to policy-related expectations of upcoming government-led volume-based procurement.
• Gross profit dropped 48.3% to RMB 146 million, while R&D expenses climbed 57.0% to RMB 92 million.
• Finance costs increased 11.3% to RMB 21.7 million; cash and cash equivalents edged down 2.2% to RMB 1.11 billion.
• U.S. FDA accepted BLAs for BA6101 and BA1102 in July 2026; BA1104 is expected to be filed for China approval in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303493), on August 27, 2026, and is solely responsible for the information contained therein.